Galera Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q3 2018 to Q3 2024

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Galera Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2018 to Q3 2024.
Galera Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$5.91M, a 55.9% increase year-over-year.
Galera Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$19.9M, a 65.3% increase year-over-year.
Galera Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$49.3M, a 3.84% increase from 2022.
Galera Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$51.2M, a 30.2% increase from 2021.
Galera Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$73.4M, a 3.99% decline from 2020.

Operating Income (Loss), Trailing 12 Months (USD)

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q3 2024	-$19.9M	-$5.91M	+$7.49M	+55.9%	Jul 1, 2024	Sep 30, 2024	10-Q	2024-12-13
Q2 2024	-$27.4M	-$4.21M	+$12.6M	+75%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-14
Q1 2024	-$40M	-$4.58M	+$9.3M	+67%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-13
Q4 2023	-$49.3M	-$5.18M	+$8.01M	+60.7%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-28
Q3 2023	-$57.3M	-$13.4M	-$438K	-3.38%	Jul 1, 2023	Sep 30, 2023	10-Q	2024-12-13
Q2 2023	-$56.8M	-$16.8M	-$4.88M	-40.9%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-14
Q1 2023	-$52M	-$13.9M	-$727K	-5.53%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-13
Q4 2022	-$51.2M	-$13.2M	+$1.31M	+9.06%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-28
Q3 2022	-$52.5M	-$13M	+$7.34M	+36.2%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-14
Q2 2022	-$59.9M	-$11.9M	+$9.16M	+43.4%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-14
Q1 2022	-$69M	-$13.2M	+$4.33M	+24.8%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-11
Q4 2021	-$73.4M	-$14.5M	+$4.45M	+23.5%	Oct 1, 2021	Dec 31, 2021	10-K	2023-03-08
Q3 2021	-$77.8M	-$20.3M	-$4.22M	-26.3%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-09
Q2 2021	-$73.6M	-$21.1M	-$3.38M	-19.1%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-09
Q1 2021	-$70.2M	-$17.5M	+$337K	+1.89%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-16
Q4 2020	-$70.6M	-$18.9M	-$2.78M	-17.2%	Oct 1, 2020	Dec 31, 2020	10-K	2022-03-10
Q3 2020	-$67.8M	-$16.1M	-$3.22M	-25.1%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-10
Q2 2020	-$64.6M	-$17.7M	-$6.44M	-57.2%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-10
Q1 2020	-$58.1M	-$17.8M	-$7.42M	-71.4%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-11
Q4 2019	-$50.7M	-$16.2M			Oct 1, 2019	Dec 31, 2019	10-K	2021-03-11
Q3 2019		-$12.9M	-$7.45M	-138%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-10
Q2 2019		-$11.3M			Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-10
Q1 2019		-$10.4M			Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-12
Q3 2018		-$5.41M			Jul 1, 2018	Sep 30, 2018	10-Q	2019-12-10

* An asterisk sign (*) next to the value indicates that the value is likely invalid.